03:19 , Nov 2, 2018 |  BC Innovations  |  Targets & Mechanisms

FDA’s pediatric target picks

FDA is looking ahead of industry in its guideline on targets for pediatric oncology, which includes more than 50 not yet in company pipelines in a list of over 220 the agency has its eye...
18:29 , Apr 20, 2018 |  Clinical Results  |  Clinical Results

Celldex discontinues development of glembatumumab vedotin after TNBC failure

Celldex Therapeutics Inc. (NASDAQ:CLDX) said IV glembatumumab vedotin (CDX-011) missed the primary endpoint of improving progression-free survival (PFS) compared with Xeloda capecitabine in the Phase IIb METRIC trial to treat metastatic triple-negative breast cancer (TNBC)...
19:11 , Apr 16, 2018 |  BC Extra  |  Clinical News

Celldex routed after TNBC failure

Celldex Therapeutics Inc. (NASDAQ:CLDX) fell $1.39 (65%) to $0.76 on Monday after it said IV glembatumumab vedotin (CDX-011) missed the primary endpoint of improving progression-free survival (PFS) compared with Xeloda capecitabine in the Phase IIb...
14:06 , May 16, 2017 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Breast cancer Cell culture and mouse studies suggest inhibiting GPNMB or its regulator MAFK could help treat breast cancer. Human triple-negative breast cancer (TNBC) cell lines expressed higher levels of MAFK than luminal- or...
20:22 , Nov 4, 2016 |  BC Week In Review  |  Clinical News

Glembatumumab vedotin: Ph II data

Data from 62 patients with unresectable stage III or IV metastatic melanoma that has progressed after checkpoint inhibitor therapy in cohort 1 of an open-label, U.S. Phase II trial showed that IV glembatumumab vedotin every...
07:00 , May 9, 2016 |  BC Week In Review  |  Clinical News

Glembatumumab vedotin: Phase I/II started

Celldex began an open-label, U.S. Phase I/II trial of IV glembatumumab vedotin given every 3 weeks in about 49 patients who have progressed on prior platinum-based chemotherapy. The dose-escalation Phase I portion will evaluate a...
01:22 , Mar 8, 2016 |  BC Extra  |  Top Story

Celldex sinks after halting GBM Phase III

Celldex Therapeutics Inc. (NASDAQ:CLDX) fell $4.40 (54%) to $3.79 on Monday after it said it will stop the Phase III ACT IV trial of Rintega rindopepimut to treat newly diagnosed glioblastoma multiforme. The decision followed...
08:00 , Dec 22, 2014 |  BC Week In Review  |  Clinical News

Glembatumumab vedotin: Phase II started

Celldex began an open-label, U.S. Phase II trial to evaluate IV glembatumumab vedotin on day 1 of each 21-day cycle in about 60 patients who have received =4 prior lines of anticancer regimens, including =1...
03:15 , Nov 6, 2014 |  BC Extra  |  Clinical News

Investors rebuff Celldex's METRICs

Celldex Therapeutics Inc. (NASDAQ:CLDX) shed $3.48 (21%) to $13.10 on Wednesday on changes to the pivotal Phase II METRIC study of glembatumumab vedotin to treat metastatic triple-negative breast cancers (TNBC) that overexpress glycoprotein NMB (...
08:00 , Dec 16, 2013 |  BC Week In Review  |  Clinical News

Glembatumumab vedotin: Phase II started

Celldex began the open-label, international, pivotal Phase II METRIC trial to compare IV glembatumumab vedotin on day 1 of each 21-day cycle vs. capecitabine in about 300 patients who have received <=1 prior lines of...